The shareholders finally own something, a patent. This is IP and will command a premium if the science proves valuable. If not then we all lose our investment. This is a high risk/high reward investment with a long time to maturity.
Too much news/sales pitches could also be bad as it sets a precedence on the rate of progress. This is perhaps the failure of the board (or certain members) in previous times, but this is the reality of the markets expectations.
Again, the awarding of the Australian patent is gold! As a shareholder you now own something. The company also has cash in the bank and (I'm assuming) will receive revenue from the Australian government grants program next year.
Things to watch out for.
1. Granting of US patents
2. A investor presentation to come later this year, expect share price to rise.
3. Institutions will be more interested in jumping on board once the US patents are awarded.
4. Further capital raising/options or placements will fund full human trials and further drug development within the patent, etc etc.
Buy/hold or sell but don't complain.
NRT Price at posting:
9.7¢ Sentiment: Hold Disclosure: Held
